Overview

Characterizing Clinical and Pharmacological Neuroimaging Biomarkers

Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
This study is part of a larger overall study that seeks to characterize clinical and pharmacological neuroimaging biomarkers. The purpose of this registered protocol is understand the effect of emotion on cognitions by specifically examining the effect of reward processing on working memory in patients with schizophrenia.
Phase:
Early Phase 1
Details
Lead Sponsor:
Yale University
Treatments:
Ketamine